Search
Returning search results with filters:
Remove filter for
Category: Biologic or vaccine
Remove filter for
Issue: Product safety
Remove filter for
Issue: COVID
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 15 of 23 items.
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17
COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton Labels: New Formulation for Use in Children 5 to Less Than 12 Years of Age
AlertHealth professional risk communication | 2022-12-09
SPIKEVAX Bivalent (Original / Omicron BA.4/5) (elasomeran/davesomeran) COVID-19 Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-11-18
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
AlertHealth professional risk communication | 2022-10-26
COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-10-07
Distribution of SPIKEVAX Bivalent (elasomeran/imelasomeran) COVID-19 Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-09-02
Distribution of a New Presentation of SPIKEVAX (elasomeran) COVID-19 Vaccine (0.10 mg/mL in 2.5 mL multidose vial) with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-06-06
Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines
AlertPublic advisory | 2021-11-09
Authorization of Sotrovimab for Injection for Use in Relation to the COVID-19 Pandemic
AlertHealth professional risk communication | 2021-10-04
Health Canada updates Pfizer-BioNTech and Moderna COVID-19 vaccine labels to include information on myocarditis and pericarditis
AlertPublic advisory | 2021-06-30
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
AlertHealth professional risk communication | 2021-06-29
Bamlanivimab - Potential Risk of Treatment Failure Due to Circulation of Resistant SARS-CoV-2 Variants
AlertHealth professional risk communication | 2021-04-28
Importation of Janssen COVID-19 Vaccine with Two Types of English-only Vial and Carton Labels
AlertHealth professional risk communication | 2021-04-26
Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels (US-Labelled Supply)
AlertHealth professional risk communication | 2021-03-31
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia
AlertHealth professional risk communication | 2021-03-24